Antibiotic treatment of bacterial lung infections in cystic fibrosis
Open Access
- 14 December 2024
- journal article
- review article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (1) , 1-10
Abstract
Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aKeywords
This publication has 82 references indexed in Scilit:
- Bronchoscopy-guided antimicrobial therapy for cystic fibrosisCochrane Database of Systematic Reviews, 2024
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisCochrane Database of Systematic Reviews, 2023
- Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosisCochrane Database of Systematic Reviews, 2022
- Inhaled antibiotics for pulmonary exacerbations in cystic fibrosisCochrane Database of Systematic Reviews, 2022
- Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationCochrane Database of Systematic Reviews, 2020
- Treatment for chronic methicillin-sensitiveStaphylococcus aureuspulmonary infection in people with cystic fibrosisCochrane Database of Systematic Reviews, 2018
- Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic FibrosisArchives of Pediatrics & Adolescent Medicine, 2011
- Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosisPediatric Pulmonology, 2010
- Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic FibrosisJAMA, 2010
- Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment ofPseudomonas aeruginosa colonization in cystic fibrosisPediatric Pulmonology, 1998